CPNE2 might serve as a new negative prognostic biomarker in gastric cancer.

IF 2.9 4区生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

3 Biotech Pub Date : 2025-09-01 Epub Date: 2025-08-29 DOI:10.1007/s13205-025-04491-3

Hasan Çağrı Yıldırım, Fatih Yay, Gökhan Şahin, Fatih Kuş, Şuayib Yalçın

{"title":"CPNE2 might serve as a new negative prognostic biomarker in gastric cancer.","authors":"Hasan Çağrı Yıldırım, Fatih Yay, Gökhan Şahin, Fatih Kuş, Şuayib Yalçın","doi":"10.1007/s13205-025-04491-3","DOIUrl":null,"url":null,"abstract":"Gastric cancer is a common malignancy with a high mortality rate. Improvement in survival has been observed with therapies targeting HER2 and Claudin 18.2 or with immune checkpoint inhibitors. Despite these advancements, the prognosis remains poor. Therefore, there is a need to identify new prognostic biomarkers that may play a role in gastric cancer and then conduct studies that can target these molecules. In this study, bioinformatics databases were utilized to analyze CPNE2 gene expression in normal and tumor samples, and its association with cancer stage was investigated. The relationship between CPNE2 gene expression and Overall Survival (OS) was analyzed. CPNE2 gene expression was significantly higher in gastric tumor samples compared to normal tissues (p < 0.05). Higher CPNE2 expression was observed in stages 2, 3, and 4 compared to stage 1. Elevated CPNE2 gene expression was associated with shorter mOS in both the GeneChip Gastric Cancer and RNAseq STAD databases. In the OS analysis using the GeneChip database, the hazard ratio (HR) was 1.72 (1.37-2.16), p = 1.8e-6, with a false discovery rate (FDR) of 1%, and a cutoff value of 311. High CPNE2 gene expression was associated with shorter FP (HR = 1.85 (1.36-2.51), P = 6e-05, FDR = 2%, cutoff value = 216). In our study, higher CPNE2 gene expression was detected in advanced-stage patients with gastric cancer compared to early-stage patients, and high CPNE2 expression was found to be associated with poor survival.Supplementary information: The online version contains supplementary material available at 10.1007/s13205-025-04491-3.","PeriodicalId":7067,"journal":{"name":"3 Biotech","volume":"15 9","pages":"319"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397100/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"3 Biotech","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13205-025-04491-3","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric cancer is a common malignancy with a high mortality rate. Improvement in survival has been observed with therapies targeting HER2 and Claudin 18.2 or with immune checkpoint inhibitors. Despite these advancements, the prognosis remains poor. Therefore, there is a need to identify new prognostic biomarkers that may play a role in gastric cancer and then conduct studies that can target these molecules. In this study, bioinformatics databases were utilized to analyze CPNE2 gene expression in normal and tumor samples, and its association with cancer stage was investigated. The relationship between CPNE2 gene expression and Overall Survival (OS) was analyzed. CPNE2 gene expression was significantly higher in gastric tumor samples compared to normal tissues (p < 0.05). Higher CPNE2 expression was observed in stages 2, 3, and 4 compared to stage 1. Elevated CPNE2 gene expression was associated with shorter mOS in both the GeneChip Gastric Cancer and RNAseq STAD databases. In the OS analysis using the GeneChip database, the hazard ratio (HR) was 1.72 (1.37-2.16), p = 1.8e-6, with a false discovery rate (FDR) of 1%, and a cutoff value of 311. High CPNE2 gene expression was associated with shorter FP (HR = 1.85 (1.36-2.51), P = 6e-05, FDR = 2%, cutoff value = 216). In our study, higher CPNE2 gene expression was detected in advanced-stage patients with gastric cancer compared to early-stage patients, and high CPNE2 expression was found to be associated with poor survival.

Supplementary information: The online version contains supplementary material available at 10.1007/s13205-025-04491-3.

查看原文本刊更多论文

CPNE2可能作为一种新的胃癌阴性预后生物标志物。

胃癌是一种常见的恶性肿瘤，死亡率高。针对HER2和Claudin 18.2或免疫检查点抑制剂的治疗已观察到生存率的改善。尽管取得了这些进展，但预后仍然很差。因此，有必要确定可能在胃癌中起作用的新的预后生物标志物，然后针对这些分子进行研究。本研究利用生物信息学数据库分析CPNE2基因在正常和肿瘤样本中的表达，并探讨其与肿瘤分期的关系。分析CPNE2基因表达与总生存期（OS）的关系。与正常组织相比，CPNE2基因在胃肿瘤样本中的表达明显升高(p CPNE2在第2、3、4期与第1期相比均有表达。在GeneChip胃癌和RNAseq STAD数据库中，升高的CPNE2基因表达与较短的mOS相关。在使用GeneChip数据库的OS分析中，风险比（HR）为1.72 (1.37-2.16),p = 1.8e-6，错误发现率（FDR）为1%，截止值为311。CPNE2基因高表达与FP较短相关（HR = 1.85 (1.36-2.51), P = 6e-05, FDR = 2%，截断值= 216）。在我们的研究中，晚期胃癌患者的CPNE2基因表达高于早期胃癌患者，并且发现CPNE2高表达与较差的生存率相关。补充资料：在线版本提供补充资料，网址为10.1007/s13205-025-04491-3。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

3 Biotech Agricultural and Biological Sciences-Agricultural and Biological Sciences (miscellaneous)

CiteScore

6.00

自引率

0.00%

发文量

314

期刊介绍： 3 Biotech publishes the results of the latest research related to the study and application of biotechnology to: - Medicine and Biomedical Sciences - Agriculture - The Environment The focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech will appeal to scientists and engineers in both academia and industry focused on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.